公开(公告)号：US20070141081A1

公开(公告)日：2007-06-21

申请号：US11705696

申请日：2007-02-13

申请人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

发明人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

IPC分类号： C12P19/34 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N9/0006 ,  C12N2770/24122 ,  Y02A50/386

摘要： The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

摘要翻译： 本发明涉及获得编码蛋白质的蛋白质的嵌合链，其能够在受体中诱导抗登革病毒感染的血清型特异性和保护性体液免疫应答，从而消除血清型非特异性病毒免疫增强的作用 导致这种病理描述的出血和临床并发症。 核酸的这些嵌合链由来自脑膜炎奈瑟氏球菌与脱氢酶活性的突变蛋白质的基因的片段的特异性组合和编入来自登革病毒的包膜（E）蛋白的区域的片段组成，当插入时 表达载体，产生具有特定性质的嵌合蛋白。 所得到的本发明的嵌合分子适用于获得用于人类的疫苗制剂和高血清型特异性的诊断方法的制药工业。

公开(公告)号：US20060193853A1

公开(公告)日：2006-08-31

申请号：US10539172

申请日：2003-12-22

申请人： Eddy Fuentes ,  Roberto Baker ,  Eulogio Vazquez ,  Jesus Barranco ,  Franklin Aguilar ,  Niurka More ,  Lesvia Aguilera ,  Hector Dominguez ,  Yovisleidys Saez ,  Gerardo Guillen Nieto ,  Glay Santiago

发明人： Eddy Fuentes ,  Roberto Baker ,  Eulogio Vazquez ,  Jesus Barranco ,  Franklin Aguilar ,  Niurka More ,  Lesvia Aguilera ,  Hector Dominguez ,  Yovisleidys Saez ,  Gerardo Guillen Nieto ,  Glay Santiago

IPC分类号： A61K39/395 ,  A61K38/24 ,  A61K38/25 ,  A61K38/17

CPC分类号： A61K39/0011 ,  A61K39/395 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6081

摘要： The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumor response which is expressed as a reduction in the tumor mass and an increase in the survival time.

摘要翻译： 本发明涉及免疫学，内分泌学和肿瘤学领域，特别是对确定的生长因子和激素的组合免疫应答的产生。 生长调节因子（EGF，TGF和VEGF）和参与性激素释放级联或繁殖（GnRH，LH，FSH）的激素之间的协同作用刺激抗肿瘤反应，其表达为 肿瘤块和生存时间增加。

公开(公告)号：US20070275012A1

公开(公告)日：2007-11-29

申请号：US10576158

申请日：2004-10-20

申请人： Julio Aguilar Rubido ,  Enrique Iglesias Perez ,  Yadira Lobaina Mato ,  Daymir Garcia Gonzalez ,  Verena Muzio Gonzalez ,  Gerardo Guillen Nieto ,  Nelson Acosta Rivero ,  Raimundo Ubieta Gomez ,  Julio Alvarez Obregon ,  Santiago Duenas Carrera ,  Carlos Duarte Cano ,  Peter Vanlandshoot ,  Luis Herrera Martinez

发明人： Julio Aguilar Rubido ,  Enrique Iglesias Perez ,  Yadira Lobaina Mato ,  Daymir Garcia Gonzalez ,  Verena Muzio Gonzalez ,  Gerardo Guillen Nieto ,  Nelson Acosta Rivero ,  Raimundo Ubieta Gomez ,  Julio Alvarez Obregon ,  Santiago Duenas Carrera ,  Carlos Duarte Cano ,  Peter Vanlandshoot ,  Luis Herrera Martinez

IPC分类号： A61K39/295 ,  A61P31/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/70 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2740/16034 ,  C12N2770/24234

摘要： The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.

摘要翻译： 本发明涉及针对引起慢性病的病原体的治疗性疫苗领域。 它包括用于治疗含有乙型肝炎表面抗原（HBsAg）作为主要化合物的制剂。 HBsAg作为重组产品在Picchia pastoris中生产。 本发明的制剂还包括乙型肝炎表面抗原和其他共同施用的抗原的组合。 除了特异性抗体的显着反应之外，所得制剂能够产生有效的淋巴细胞扩增和细胞毒性应答，这使得它们在治疗这些疾病方面非常有效。

公开(公告)号：US20070166333A1

公开(公告)日：2007-07-19

申请号：US10577000

申请日：2004-11-03

申请人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

发明人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

IPC分类号： A61K39/095 ,  C12N15/74 ,  C12N1/21

CPC分类号： C07K14/22 ,  A61K39/00

摘要： Method for the insertion of protein antigens, of recombinant or synthetic origin, in outer membrane vesicles of Gram-negative bacteria without disruption of the vesicle structure, therefore maintaining the immunogenicity and immunostimulatory properties of said vesicles, and with the reported advantage that the immune response generated against the incorporated antigen is superior to the one generated when the antigen is administered alone. The resultant vaccine formulations are useful to increase protective capacity of existing vaccines and allow to extend it against different pathogens, in diseases of bacterial, viral, cancerous or other etiology. The referred formulations are applicable in the pharmaceutical industry as vaccines for therapeutic and preventive use in humans.

摘要翻译： 在革兰氏阴性细菌的外膜囊泡中插入重组或合成来源的蛋白质抗原的方法，而不破坏囊泡结构，从而保持所述囊泡的免疫原性和免疫刺激性质，并且报告的优点是免疫应答 针对所掺入的抗原产生的抗原优于单独施用抗原时产生的抗原。 所得的疫苗制剂可用于增加现有疫苗的保护能力，并允许其在细菌，病毒，癌性或其它病因学疾病中扩展到不同的病原体。 所提及的制剂在制药工业中可用作人类治疗和预防用途的疫苗。

公开(公告)号：US20050107294A1

公开(公告)日：2005-05-19

申请号：US10499457

申请日：2002-12-04

申请人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

发明人： Jorge Acosta ,  Jose Fernandez Montequin ,  Calixto Valdes Perez ,  Neobalis Perez ,  Ingrid Constantin ,  Hector Milian ,  Larissa Corvea ,  Gerardo Guillen Nieto ,  Luis Martinez ,  Leonardo Canan-Haden Frias ,  Haydee Geronimo Perez ,  Jorge Sotolongo Pena

IPC分类号： A61K9/08 ,  A61K9/14 ,  A61K9/19 ,  A61K38/00 ,  A61K38/18 ,  A61P9/10 ,  A61P17/02 ,  C07K14/485

CPC分类号： A61K38/1808

摘要： The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.

摘要翻译： 本发明涉及在优选可注射的药物组合物中使用表皮生长因子（EGF），其通过渗入慢性皮肤缺血性损伤中及其周围而被施用，以防止糖尿病足部截肢。 所述组合物可以施用于由于长时间缺血引起的急性再灌注与氧合血液的影响而损伤的近期产生的手术表面，从而防止进一步的外科手术并有利于肢体的保存。 上述组合物可用于改善（i）细胞微环境，从而增加组织的修复和防御能力和活力，以及（ii）皮肤缺血性损伤的瘢痕化，从而刺激细胞增殖。 本发明适用于人类，兽医和实验医学，特别适用于血管病变和手术，皮肤病学，烧伤治疗和重建手术以及老年医学。 所述组合物可用于与宏观和/或微血管系统中的病变相关的顽固性溃疡，淋巴和/或静脉回流不足的患者以及难以发rise和/或愈合的溃疡或其它病变。